<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462330</url>
  </required_header>
  <id_info>
    <org_study_id>10 142 01</org_study_id>
    <nct_id>NCT02462330</nct_id>
  </id_info>
  <brief_title>Administration of Mesenchymal Stem Cells in Patients With Chronic Ischemic Cardiomyopathy (MESAMI2)</brief_title>
  <acronym>MESAMI2</acronym>
  <official_title>Effect of Intramyocardial Mesenchymal Stem Cells Injection in Patients With Chronic Ischemic Cardiomyopathy and Left Ventricular Dysfunction Guide by NogaStar XP System Catheter.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stem cell therapy is an emerging treatment for cardiovascular disease but the best cell type
      and delivery method remain to be determined. Pre-clinical studies demonstrated improvement of
      cardiac function by Mesenchymal stem cells (MSC) therapy in particular by their paracrine and
      immunosuppressive properties. Investigators initiated the MESAMI program by the bicentric
      pilot phase and highlighted the safety and feasibility of intramyocardial injections of MSCs
      from bone marrow in patients with chronic ischemic cardiomyopathy and left ventricular
      dysfunction, guide by the NOGA-XP system. The MESAMI program continues with the phase 2,
      multicenter, double-blind, randomized, placebo-controlled trial.The aim of this phase 2 study
      is to demonstrate a functional improvement, measuring peak VO2, at 3 months between the cell
      therapy group and the placebo group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ischemic cardiomyopathies are a leading cause of death in both men and women. During the last
      decade, treatments for heart failure have evolved, but their purpose is to improve symptoms
      and prevent aggravation of the disease. Current research is focusing on the development of
      cell-based therapies using different sources of stem cells which can provide trophic and
      paracrine support or even replace dying cells with new ones. A specific form of stem cells,
      called adult mesenchymal stem cells (MSCs), has shown promise for heart repair. These cells
      are known for their ability to secrete paracrine factors and their immunosuppressive
      properties. The MESAMI 2 study will evaluate the efficacy of MSCs injection directly into the
      heart to repair and restore heart function in people with chronic ischemic heart failure
      using NOGA-XP system.

      This phase 2 study is a prospective, multicenter, double-blind, randomized,
      placebo-controlled trial. A total of 90 patients will be randomized in 2 arms to receive
      intramyocardial injection of MSCs or placebo. Patients will be followed up for 13 months.
      Bone marrow will be collected and immediately transported to the French Blood Establishment
      for MSC isolation and expansion. Patients will receive intramyocardial injection of MSCs or
      placebo during a left heart catheterization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in VO2max</measure>
    <time_frame>3 months</time_frame>
    <description>Change in VO2max (or peak VO2) before injection and at 3 months post injection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular viability</measure>
    <time_frame>Before injection and at 3, 6 and 12 months</time_frame>
    <description>MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA/CCS class</measure>
    <time_frame>Before injection and at 3, 6 and 12 months</time_frame>
    <description>Change on class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (Minnesota questionnaire)</measure>
    <time_frame>Before injection and at 3, 6 and 12 months</time_frame>
    <description>Change on quality of life test score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VO2 max</measure>
    <time_frame>At 6 and 12 months</time_frame>
    <description>Change in VO2max (or peak VO2) at 6 and 12 months post injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6'walking-test</measure>
    <time_frame>Between 3 and 12 months</time_frame>
    <description>Distance to walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>Before injection and at 3, 6 and 12 months</time_frame>
    <description>Volume of myocardium and measurement of ejection fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial perfusion imaging</measure>
    <time_frame>Before injection and at 3, 6 and 12 months</time_frame>
    <description>Efficacy of the cell therapy on LVEF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BNP blood test</measure>
    <time_frame>Before injection and at 3, 6 and 12 months</time_frame>
    <description>Change of the BNP blood test at 3, 6 and 12 months</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse event related to cell administration</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Complication related to cell administration</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Control of the implantable cardioverter defibrillator</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of major cardiovascular events</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Chronic Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>injection of human albumin 4%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autologous MSC from bone marrow</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intramyocardial injection of 6.10e7 stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Autologous MSC from bone marrow</intervention_name>
    <description>After bone-marrow aspiration by an authorized person, MSCs were isolated and cultured during 17±2 days by the French Blood Establishment. Then, patients receive intramyocardial injections of MSCs using the electromechanical NOGA-XP system.</description>
    <arm_group_label>Autologous MSC from bone marrow</arm_group_label>
    <other_name>mesenchymal stem cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>injections of human albumin</description>
    <arm_group_label>Placebo comparator</arm_group_label>
    <other_name>Human Albumin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who signed the informed consent,

          -  Chronic stable ischemic cardiomyopathy for at least one month with a NYHA Class II-IV
             and/or -Angina pectoris CCS Class III or IV,

          -  Not a candidate for revascularization by coronary artery by-pass surgery or
             angioplasty,

          -  Left ventricular function ≤45%,

          -  Presence of ischemia or myocardial viability on the myocardial perfusion imaging,

          -  VO2 max≤ 20 ml/min/kg,

          -  Optimal medical therapy,

          -  Optimal interventional therapy (Implantable Cardiovertor Defibrillator, effort
             rehabilitation).

        Exclusion criteria:

          -  Pregnancy or breastfeeding,

          -  Acute coronary syndrome or myocardial infarction during the last 3 months,

          -  Revascularization (PCI or CABG), or cardiac resynchronization during the last 3
             months,

          -  Further revascularization planned for the next 30 days,

          -  LVEF &gt;45%,

          -  Left intraventricular Thrombus and / or ventricular aneurysm detected by transthoracic
             echocardiography,

          -  Wall thickness in the target region &lt;8 mm as determined by echocardiography,

          -  Critical Limb Ischemia stages 3 or 4,

          -  Inability to achieve a VO2 test,

          -  Not feasible peripheral arterial access for percutaneous procedure,

          -  Aortic stenosis (&lt;1cm²) or aortic insufficiency (&gt; 2 +),

          -  Patients with transplanted organ,

          -  Chronic renal failure with creatinemia ≥ 250 µmol/L,

          -  Severe hepatic dysfunction,

          -  Chronic atrial fibrillation,

          -  Decompensated heart failure,

          -  Uncontrolled Ventricular arrhythmias,

          -  Indication of cardiac resynchronization by multisite pacemaker or cardiac
             resynchronization during the last 3 months,

          -  Obesity preventing bone marrow aspiration or manual compression of the puncture area
             after bone marrow collection,

          -  Active uncontrolled infection

          -  Immuno-modulator treatment (ciclosporin, mycophenolate, mycophenolate mofetil,
             azathioprine, tacrolimus, anthracyclines, neupogen, hydrea, etanercept interferons,
             prednisolone, methylprednisolone, colchicine),

          -  History of cancer in the last 5 years,

          -  Hemopathy, hematopoietic disease,

          -  Haemorrhagic syndrome,

          -  Chronic or progressive disease that may alter the prognosis within 3 months,

          -  Positive serologies for Human immunodeficiency virus (HIV1-2), HTLV-1 (human T-cell
             lymphotrophic virus) and 2, HBV (hepatitis B virus) or HCV (hepatitis B virus).

          -  Allergic to xylocain.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerôme Roncalli, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toulouse University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jerôme Roncalli, MD, PhD</last_name>
    <phone>05 61 32 26 13</phone>
    <phone_ext>+33</phone_ext>
    <email>roncalli.j@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amandine Pauze</last_name>
    <phone>05 61 77 84 34</phone>
    <email>pauze.a@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University hospital of Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Teiger, MD, PhD</last_name>
      <phone>01 49 81 21 11</phone>
      <phone_ext>+33</phone_ext>
      <email>emmanuel.teiger@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel Teiger, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yannick Neuder</last_name>
      <phone>04 76 76 84 66</phone>
      <phone_ext>+33</phone_ext>
      <email>YNeuder@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Yannick Neuder, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Van Belle, MD, PhD</last_name>
      <phone>03 20 44 59 62</phone>
      <phone_ext>+33</phone_ext>
      <email>ericvanbelle@aol.com</email>
    </contact>
    <investigator>
      <last_name>Eric Van Belle, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Noël Trochu, MD, PhD</last_name>
      <phone>02 40 16 52 77</phone>
      <phone_ext>+33</phone_ext>
      <email>jeannoel.trochu@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Noël Trochu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Isnard, MD, PhD</last_name>
      <phone>01 42 16 30 09</phone>
      <phone_ext>+33</phone_ext>
      <email>richard.isnard@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Richard Isnard, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiology Department of Rangueil Hospital - Rangueil Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerôme Roncalli, MD, PhD</last_name>
      <phone>05 61 32 26 13</phone>
      <phone_ext>+33</phone_ext>
      <email>roncalli.j@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marine Lebrin</last_name>
      <phone>05 61 32 37 24</phone>
      <phone_ext>+33</phone_ext>
      <email>lebrin.m@chu-toulouse.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jerôme Roncalli, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>ischemic cardiomyopathy</keyword>
  <keyword>NogaStar XP system catheter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

